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ABSTRACT Bacterial resistance against antibiotics often involves multiple mecha-
nisms that are interconnected to ensure robust protection. So far, the knowledge
about underlying regulatory features of those resistance networks is sparse, since
they can hardly be determined by experimentation alone. Here, we present the ﬁrst
computational approach to elucidate the interplay between multiple resistance mod-
ules against a single antibiotic and how regulatory network structure allows the cell
to respond to and compensate for perturbations of resistance. Based on the re-
sponse of Bacillus subtilis toward the cell wall synthesis-inhibiting antibiotic bacitra-
cin, we developed a mathematical model that comprehensively describes the pro-
tective effect of two well-studied resistance modules (BceAB and BcrC) on the
progression of the lipid II cycle. By integrating experimental measurements of ex-
pression levels, the model accurately predicts the efﬁcacy of bacitracin against the B.
subtilis wild type as well as mutant strains lacking one or both of the resistance
modules. Our study reveals that bacitracin-induced changes in the properties of the
lipid II cycle itself control the interplay between the two resistance modules. In par-
ticular, variations in the concentrations of UPP, the lipid II cycle intermediate that is
targeted by bacitracin, connect the effect of the BceAB transporter and the homeo-
static response via BcrC to an overall resistance response. We propose that monitor-
ing changes in pathway properties caused by a stressor allows the cell to ﬁne-tune
deployment of multiple resistance systems and may serve as a cost-beneﬁcial strat-
egy to control the overall response toward this stressor.
IMPORTANCE Antibiotic resistance poses a major threat to global health, and system-
atic studies to understand the underlying resistance mechanisms are urgently needed.
Although signiﬁcant progress has been made in deciphering the mechanistic basis of in-
dividual resistance determinants, many bacterial species rely on the induction of a whole
battery of resistance modules, and the complex regulatory networks controlling these
modules in response to antibiotic stress are often poorly understood. In this work we
combined experiments and theoretical modeling to decipher the resistance network of
Bacillus subtilis against bacitracin, which inhibits cell wall biosynthesis in Gram-positive
bacteria. We found a high level of cross-regulation between the two major resistance
modules in response to bacitracin stress and quantiﬁed their effects on bacterial resis-
tance. To rationalize our experimental data, we expanded a previously established com-
putational model for the lipid II cycle through incorporating the quantitative action of
the resistance modules. This led us to a systems-level description of the bacitracin stress
response network that captures the complex interplay between resistance modules and
the essential lipid II cycle of cell wall biosynthesis and accurately predicts the minimal in-
hibitory bacitracin concentration in all the studied mutants. With this, our study high-
lights how bacterial resistance emerges from an interlaced network of redundant ho-
meostasis and stress response modules.
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Computational approaches signiﬁcantly improved our understanding of bacterialresponses to environmental conditions, which often comprise multiple intercon-
nected modules orchestrated in complex regulatory networks. For instance, mathemat-
ical modeling elucidated differences in signaling and signal processing in bacterial
chemotaxis in Bacillus subtilis and Escherichia coli (1, 2), contributed to our understand-
ing of how environmental and cellular conditions shape the complex phosphorelay
system controlling sporulation and competence in B. subtilis (3–5), and helped to
uncover the regulatory mechanisms of F-dependent sporulation control in Bacillus
subtilis (6, 7). In all of these studies, the overall cellular response toward environmental
changes was shown to involve an intricate interplay between different regulatory
modules, which can hardly be understood without theoretical frameworks.
The cell envelope stress response (CESR) is another example of a particularly
important, multilayered regulatory network in bacteria, as it provides effective protec-
tion against crucial cell wall-targeting antibiotics, including the antimicrobial peptides
(AMPs) bacitracin (BAC), ramoplanin, and vancomycin. In many bacteria, the CESR
involves orchestrated expression of various resistance determinants that protect
against these AMPs via an array of mechanisms (8). These include, for instance, changes
in cell envelope composition to shield cellular targets from AMPs (9), production of
resistance pumps to remove AMPs from their site of action (10), enzymatic or genetic
modiﬁcations of target structures to prevent AMP binding (11), or the synthesis of
immunity proteins to degrade AMPs altogether (12). Although many of the resistance
mechanisms are well described and we have a good understanding of the gene
regulatory control of individual resistance modules, the complex interplay and cross-
regulation between individual resistance modules remain poorly understood. Given
that 8 out of the 12 bacterial pathogens on the WHO’s priority list have acquired
resistance toward cell wall-targeting antibiotics (https://www.who.int/news-room/
detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are
-urgently-needed), theoretical models rationalizing the cellular response toward such
drugs are urgently needed.
To address this knowledge gap, we focused in this study on the resistance network
of B. subtilis toward BAC, an AMP that interferes with the lipid II (LII) cycle of cell wall
biosynthesis (Fig. 1) (13). Brieﬂy, within this essential pathway the peptidoglycan (PG)
precursors N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc)-
pentapeptide are sequentially attached to the lipid carrier molecule undecaprenyl
phosphate (UP) by MraY and MurG, thereby forming lipid II (Fig. 1). Subsequently, lipid
II is ﬂipped across the cytoplasmic membrane via the ﬂippases MurJ and Amj, where the
PG monomer (GlcNAc-MurNAc-pentapeptide) is incorporated into the growing cell wall
by various redundant penicillin-binding proteins (PBPs). This leaves the lipid carrier in
its pyrophosphate form (UPP), which has to be recycled to UP by dephosphorylation (in
B. subtilis via the UPP phosphatases BcrC, UppP, and, to a minor degree, YodM) (14–16)
to allow a new round of PG monomer transport. Bacitracin blocks the cycle by forming
a tight complex with UPP (UPP-BAC), which efﬁciently prevents recycling of the lipid
carrier and ultimately leads to lysis of cells (17, 18). Like in many Gram-positive bacteria,
bacitracin resistance in B. subtilis is mediated by multiple resistance determinants,
which are transcriptionally upregulated in response to bacitracin treatment (reviewed
in reference 19). The most effective (primary) resistance determinant is the ABC
transporter BceAB (20), which protects UPP from the inhibitory grip of bacitracin
(Fig. 2A)—presumably by breaking UPP-BAC complexes and thereby shifting the
binding equilibrium toward the free form of UPP (21). The second line of defense is
mediated by the UPP phosphatase BcrC, which increases the rate of UPP dephosphor-
ylation and thereby promotes progression of the lipid II cycle (14, 15, 22, 23) (Fig. 2A).
Simultaneously, B. subtilis induces production of the phage shock-like proteins LiaI and
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LiaH (22, 24), which play only a minor role in bacitracin resistance and seem to be
involved in stabilization of membrane integrity by a mechanism that is yet to be
determined (25, 26).
Expression of bceAB is activated by a two-component system comprising the
histidine kinase BceS and the response regulator BceR (15, 20, 22, 27, 39). BceS forms
a sensory complex with BceAB in the membrane (28, 29), which acts as a “ﬂux sensor”
reporting on the antibiotic load experienced by each individual transporter—thereby
activating further transporter expression only if their detoxiﬁcation capacity ap-
proaches saturation (21). Expression of BcrC is primarily controlled by the extracyto-
plasmic function sigma factor M (14, 30). While the physiological input triggering
activation of M still remains elusive (31, 32), the broad range of inducing conditions,
including cell wall antibiotics, salt, ethanol, and others, suggests that it is not a speciﬁc
chemical compound but rather a cellular cue upon cell envelope damage that activates
the M response (33). Interestingly, despite the seemingly unrelated input stimuli for
the BceAB and the BcrC resistance modules—with BceAB being activated by a “drug-
sensing” mechanism (antibiotic ﬂux) and BcrC by a “damage-sensing” mechanism—
previous work revealed that there is a high level of interdependency between the
modules (26). In particular, in mutants lacking the ABC transporter BceAB, the second-
ary layers of resistance are induced more strongly and vice versa, suggesting that this
compensatory regulation is the origin of robust cell wall homeostasis in B. subtilis.
In this study, we set out to decipher the regulatory interplay between these two
FIG 1 Scheme of the cell wall biosynthetic pathway and its inhibition by bacitracin. The lipid II cycle of
cell wall biosynthesis is responsible for the translocation of PG precursors across the cytoplasmic
membrane and represents the rate-limiting step in this process. The cytoplasmic production of UDP-
MurNAc-pentapeptide (M) from UDP-GlcNAc (G) is catalyzed by the MurA to -F ligases. Subsequently, at
the internal leaﬂet of the cytoplasmic membrane the translocase MraY and the transferase MurG
sequentially attach UDP-MurNAc-pentapeptide and UDP-GlcNAc to the lipid carrier undecaprenyl phos-
phate (UP), giving rise to the lipid I and lipid II intermediates, respectively. Various ﬂippases translocate
lipid II to the outer leaﬂet of the cytoplasmic membrane, where penicillin-binding proteins (PBPs)
incorporate the subunits into the growing PG layer. In order to recycle the resulting pyrophosphorylated
state of the lipid carrier (UPP), dephosphorylation by UPP phosphatases (UppPs), including BcrC, yield the
initial substrate UP for another round of PG subunit transport. Lipid carrier recycling requires ﬂipping of
UP to the internal leaﬂet by a yet-unknown mechanism. Finally, dilution of lipid carriers is counterbal-
anced by cytoplasmic synthesis of UPP, which involves the isoprenoid biosynthesis pathway with the
undecaprenyl pyrophosphate synthetase UppS catalyzing the last committed step. Like for UP ﬂipping,
the required mechanism to present UPP to the externally acting phosphatases is unknown. Bacitracin
inhibits the lipid II cycle by binding to UPP, thereby preventing UPP dephosphorylation and progression
of the cycle.
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FIG 2 Modular composition of the bacitracin stress response network and its experimental analysis in B. subtilis. (A) Our theoretical
model of the bacitracin stress response network is based on three interconnected modules. At the core of the model is a previously
established theoretical description of the lipid II cycle module (center diagram), which predicts the PG synthesis rate (jPG) of a B. subtilis
strain devoid of any inducible resistance determinants under antibiotic perturbation (34). The dynamic variables within the model are
the concentrations of the lipid II cycle intermediates (blue spheres) in the inner and outer leaﬂet of the cytoplasmic membrane, as
indicated by the subscripts IN and OUT. To arrive at a model for wild-type cells, we ﬁrst incorporated the action of the M module
(left diagram), in which an unknown cue activates the anti- factors YdhL and YhdK in response to cell envelope stress, triggering the
release of M and the concomitant upregulation of BcrC and an array of further M-dependent genes. As a second module we
incorporated the action of the ABC transporter BceAB (right diagram), in which a complex of the histidine kinase BceS and the BceAB
transporter jointly act as a sensor for bacitracin ﬂux, triggering phosphorylation of the response regulator BceR and concomitant
upregulation of bceAB expression. Both resistance modules are qualitatively expected to increase resistance (lower diagram) by
shifting the bacitracin concentration at which the PG synthesis rate reaches its half-maximal level (IC50) to higher values. (B)
Experimental analysis of resistance module gene expression and their impact on the growth rate. Shown are target promoter activities
of PbcrC-luxABCDE (i) and PbceA-luxABCDE (iii) in B. subtilis strains carrying indicated deletions of resistance modules, as given by speciﬁc
luciferase activity (RLU/OD600) 1 h after addition of indicated amounts of bacitracin. Panel ii shows the corresponding normalized
growth rates, which are obtained as the average growth rates of strains carrying the different reporter constructs but sharing the same
genotype. Measurements were performed during exponential growth phase in LB medium at 37°C in a microtiter plate reader. Data
are shown for strains TMB1619 (wild-type strain W168 sacA::pCHlux103 [PbceA-lux]), TMB1620 (wild-type strain W168 sacA::pCHlux104
[PbcrC-lux]), TMB1623 (W168 bceAB::kan sacA::pCHlux103 [PbceA-lux]), TMB1624 (W168 bceAB::kan sacA::pCHlux104 [PbcrC-lux]), TMB1627
(W168 bcrC::tet sacA::pCHlux103 [PbceA-lux]), TMB1628 (W168 bcrC::tet sacA::pCHlux104 [PbcrC-lux]), and TMB1632 (W168 bceAB::kan
bcrC::tet sacA::pCHlux104 [PbcrC-lux]) (Table S1). Data points and error bars indicate means and SDs derived from at least three
biological replicates. Note that we did not test PbceA-luxABCDE activity in strains carrying a ΔbceAB deletion, because the ﬂux-sensing
mechanism activating PbceA strictly relies on the presence of BceAB (21). The colored stars indicate the experimental MIC values,
calculated as the concentration at which a linear interpolation between the data points crosses the zero line. In case of the wild-type
strain, the MIC was calculated by a linear extrapolation to the zero line, given that the highest concentration tested did not fully inhibit
growth. n.a., not applicable.
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resistance determinants by considering the dynamics of the lipid II cycle as a pivotal
connection between drug- and damage-sensing resistance modules. To this end, we
took advantage of a recently established computational model for the lipid II cycle,
which describes the dynamics of PG synthesis based on biochemical parameters of the
involved enzymes and cycle intermediates (34). By integrating the existing mathemat-
ical description of the lipid II cycle with a previously established model for BceAB
resistance module (21) and a novel theoretical description of the BcrC module (Fig. 2A),
we developed a systems-level description of the bacitracin stress response that cap-
tures the MIC of a wild-type (WT) B. subtilis strain, as well as several mutants deleted for
resistance systems individually or in combination. Additionally, our theoretical and
experimental analyses reveal that an increased total number of lipid carriers, i.e., the
sum of UP, UPP, lipid I, and lipid II, and an accumulation of the lipid carrier UPP in a
ΔbcrC mutant are the origin of the signiﬁcantly higher impact of the BceAB resistance
module on bacitracin resistance when BcrC is lacking. As our model does not include
any additional layers of regulation, our results show that the properties of the lipid II
cycle itself contribute to the homeostatic control of the overall resistance response
toward bacitracin. Thus, the theory presented here not only provides a comprehensive
quantitative description of the bacitracin resistance network in B. subtilis but also
uncovers regulatory mechanisms of the multilayered response toward this antibiotic.
RESULTS
The common purpose of the UPP phosphatase BcrC and the ABC transporter BceAB
is to ensure progression of the lipid II cycle under bacitracin treatment, since bacitracin
inhibits an important step of this cycle (Fig. 2A). Consequently, to study the impact of
the two resistance modules on lipid II cycle homeostasis, we successively integrated the
resistance modules into a detailed computational description of the lipid II cycle (34).
This previously established theory predicts the rate of peptidoglycan synthesis (jPG) of
a B. subtilis strain devoid of any inducible resistance determinants under antibiotic
perturbation (Fig. 2A, upper central diagram) and thus served as the basis of our
mathematical model of the overall bacitracin resistance network. In the ﬁrst step, we
included the BcrC module and studied its protective effect on the lipid II cycle (Fig. 2A,
left diagram). In a second step, we investigated the interaction of the two resistance
modules by integrating the preexisting theory of the BceAB module (21) into the model
(Fig. 2A, right diagram). In this full model, we were able to study the impact of the two
modules on bacitracin resistance by quantifying the shift in the bacitracin concentra-
tion at which the PG synthesis rate reaches its half-maximal level (IC50) to higher values
(Fig. 2A, lower diagram).
Impact of the UPP phosphatase BcrC on bacitracin resistance. In our previous
computational description of the lipid II cycle (34), we made the simplifying assumption
that the enzymes involved in lipid II cycle progression feature constant expression
levels under antibiotic treatment, but it is known that the UPP phosphatase BcrC is
upregulated in response to bacitracin treatment. Also, the model did not include the
activity of the BceAB transporter and therefore was only able to predict the approxi-
mate MIC for bacitracin in a ΔbceAB mutant strain of B. subtilis (34). Thus, the ﬁrst step
in arriving at a more realistic description of lipid II cycle homeostasis was to include the
bacitracin-dependent upregulation of bcrC expression into our computational model
for the ΔbceAB mutant strain. To experimentally assess bcrC expression in response to
bacitracin treatment under our experimental conditions, we integrated a PbcrC-
luxABCDE reporter construct into the chromosome of a ΔbceAB mutant and measured
luciferase activity 1 h after addition of various bacitracin levels (Fig. 2Bi, green). The
PbcrC promoter activity clearly correlated with increasing levels of bacitracin, leading to
a maximal 6-fold induction at 3 g/ml of bacitracin compared to that under the
untreated condition. In contrast, wild-type cells displayed only an 3-fold PbcrC induc-
tion reached at 10-fold-higher bacitracin levels (30 g/ml) (Fig. 2Bi, black), suggesting
that the additional expression of bceAB in the wild type mitigates the demand for bcrC
expression, as discussed further below. Furthermore, we investigated the impact of the
Modeling Bacitracin Resistance in B. subtilis
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BcrC resistance module on bacitracin resistance by comparing the growth of a ΔbceAB
mutant and a ΔbceAB ΔbcrC double mutant. In doing so, we were able to study the
resistance contribution of BcrC alone and avoided any compensatory upregulation of
bceAB expression that may complicate the interpretation of a comparison between the
wild type and a ΔbcrC mutant strain. By deﬁning the MIC as the lowest antibiotic
concentration leading to zero growth rate after bacitracin addition, we observed a
2.3-fold-lower MIC value for the ΔbceAB ΔbcrC mutant (Fig. 2Bii, light blue star;
MICΔbceABΔbcrC, 6.3 g/ml) compared to the ΔbceAB mutant (Fig. 2Bii, green star;
MICΔbceAB, 14.5 g/ml), consistent with earlier results (26). This clearly conﬁrmed that
the BcrC resistance module by itself contributes signiﬁcantly to the growth of B. subtilis
under bacitracin treatment.
Next, we incorporated the observed upregulation of bcrC into our existing model of
the lipid II cycle, with the goal of accurately predicting the antibiotic susceptibility
toward bacitracin in the ΔbceAB mutant strain. Brieﬂy, the previous model of the lipid
II cycle (34) considered Michaelis-Menten kinetics for all characterized enzymes, while
the mostly unknown ﬂipping reactions of the intermediates UPP, UP, and lipid II were
described by ﬁrst-order kinetics (see Text S1 in the supplemental material for a detailed
description of the model). To integrate the different levels of bcrC expression in
response to bacitracin into our model, we modiﬁed the mathematical description of the
dephosphorylation reaction of UPP. Since the speed of every enzymatic reaction within
the lipid II cycle is proportional to the concentration of the enzymes that catalyze the
reaction—according to Michaelis-Menten theory—the bacitracin-induced increase in
BcrC levels implies an increase in the speed of UPP dephosphorylation (Fig. 3A and C).
However, in B. subtilis the dephosphorylation of UPP is additionally catalyzed by a
second phosphatase, UppP, the expression of which is independent of bacitracin
(14–16) (Fig. 3B). Thus, the total speed of the UPP dephosphorylation reaction is
proportional to the weighted sum of the bacitracin-dependent contribution from BcrC
and the bacitracin-independent contribution from UppP (Fig. 3C), as indicated in
equation 1.
rate of UPP dephosphorylation  xBcrC fBcrC(BAC) [1 xBcrC] 1 (1)
Here, the factor xBcrC quantiﬁes the fractional contribution of BcrC and 1  xBcrC the
fractional contribution of UppP to the total phosphatase activity in the absence of
bacitracin. Moreover, the upregulation of BcrC levels under bacitracin treatment leads
to a fold induction of the UPP phosphatase activity according to the factor f BcrC (BAC),
which ranges from 1 to a maximal fold change (Fig. 3A). Thus, the stronger the
contribution of BcrC toward the overall phosphatase activity (higher xBcrC), the more
pronounced the acceleration of the UPP dephosphorylation reaction in response to
bacitracin (Fig. 3C). To determine the unknown parameter xBcrC, we ﬁrst assumed that
the BcrC protein level is proportional to the detected luminescence output from the
PbcrC-luxABCDE reporter in the bceAB mutant (Fig. 2Bi). We then simulated the model of
the lipid II cycle for different values of xBcrC and monitored how the upregulation of
BcrC in response to bacitracin affected the overall rate of PG synthesis (Fig. 3D). Here,
it turned out that in the case of negligible impact of BcrC to the total phosphatase
activity (xBcrC  0), the UPP phosphatase remains constant for all bacitracin concen-
trations, such that the PG synthesis rate decreases hyperbolically with increasing
bacitracin concentration, as seen before (34). In contrast, for high values of xBcrC, i.e., in
the case that the total phosphatase activity is dominated by BcrC, the upregulation of
BcrC (and thus phosphatase activity) leads to a speed-up (and thus to a peak) of the PG
synthesis rate at intermediate bacitracin levels. Ultimately, this shifts the IC50 value—
the antibiotic concentration reducing the PG synthesis rate to 50% of its unperturbed
rate—to a higher value. Studying the dependence of the predicted IC50 values on
different values of xBcrC showed that the IC50 matched the experimentally measured
MIC of the ΔbceAB mutant when UppP and BcrC made approximately equal contribu-
tions to the overall phosphatase activity (Fig. 4A).
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The total amount of lipid carrier is increased under bcrC deletion to ensure a
close-to-optimal PG synthesis rate. If the two phosphatases make approximately
equal contributions to the overall phosphatase activity, one would predict that the
deletion of one of the phosphatases should have signiﬁcant impact on cellular physi-
ology even in the absence of cell wall antibiotics. In fact, within our model the deletion
of bcrC signiﬁcantly reduces the speed of the dephosphorylation reaction of the lipid
II cycle, leading to an accumulation of UPP compared to that in a model with wild-type
bcrC activity (Fig. 5A and B). Given that the lipid II cycle can be approximated as a
closed-loop system in which the total amount of lipid intermediates running through
the cycle stays constant (34), the accumulation of UPP simultaneously reduces the
concentrations of all other lipid II cycle carriers (Fig. 5B). In addition, especially the
shortage of lipid II directly leads to a distinct reduction of the overall rate of PG
synthesis of the lipid II cycle, since lipid II ultimately releases the PG monomers for
incorporation into the cell wall (see theoretical description of the PG synthesis rate in
the supplemental material). Hence, within the simulated range of BcrC and UppP
contributions to the overall phosphatase activity, the lack of BcrC was predicted to
reduce the rate of PG synthesis below its half-maximum for some of the parameters
tested. Furthermore, the model predicted relatively low IC50 values since the overall PG
FIG 3 Different contributions of BcrC and UppP to the overall UPP phosphatase activity lead to variable
levels of protection against bacitracin. To capture the inﬂuence of the BcrC module to lipid II cycle
homeostasis, the bacitracin-dependent induction proﬁles of the two phosphatases corresponding to bcrC
(A) and uppP (B) were used as proxies for their contributions to the total UPP phosphatase activity. Given
that no biochemical characterization regarding the relative phosphatase activities of the two proteins
exists, we introduce the parameter xBcrC describing the relative contribution of BcrC (and 1  xBcrC the
contribution of UppP) to the overall phosphatase activity in the absence of bacitracin. The bacitracin-
dependent overall phosphatase activity varies according to these impacts of BcrC and UppP, as
illustrated in panel C. Integrating the bacitracin-dependent UPP phosphatase activity in panel C in the
model for the lipid II cycle (34) leads to predictions for the PG synthesis rate in panel D. This shows that
the stronger the contribution by xBcrC, the higher the bacitracin concentration at which the PG synthesis
rate reaches its half-maximal value, which we deﬁne as the IC50. Previous work showed that the IC50
serves as a good proxy for the experimental MIC for various cell wall antibiotics (34).
Modeling Bacitracin Resistance in B. subtilis
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synthesis rate was already reduced and very small amounts of bacitracin should be
sufﬁcient to further decrease it to the assumed critical rate of 50% of its optimal level.
However, such a reduction in the overall rate of PG synthesis even without bacitracin
treatment would cause clear defects in cell growth, which was observable neither in the
absence of bacitracin nor under low bacitracin concentrations when monitoring the
growth of the ΔbceAB ΔbcrC mutant strain. Instead, the growth rate of the double
mutant was only slightly affected without bacitracin (Fig. S1) and the experimentally
determined MIC (Fig. 2Bii, light blue) was signiﬁcantly higher than the IC50 values
predicted by the model. These results led us speculate that B. subtilis uses additional
routes to respond to the deletion of bcrC—thereby ensuring a close-to-optimal rate of
PG synthesis—probably by increasing the concentrations of lipid II. How does the cell
implement this homeostatic control? As previous studies revealed, M not only regu-
lates the expression of bcrC in response to bacitracin but also induces individual steps
of the methylerythritol phosphate (MEP) pathway (e.g., the ispDF operon), which is
responsible for early steps of lipid carrier (UPP) synthesis (30, 35). Indeed, it was shown
that the expression of M itself is signiﬁcantly increased in a mutant strain lacking BcrC
(15). Hence, we hypothesized that the lipid II concentrations might be homeostatically
regulated by M-dependent control of the production of new lipid carrier. To test this
hypothesis, we used reverse transcription-quantitative PCR (RT-qPCR) to quantify tran-
script levels of M-regulated genes involved in the production of UPP synthesis. As
illustrated in Fig. 4B, we found that during exponential growth in LB medium (without
bacitracin), expression of both ispD and ispF was 2-fold higher in the bcrC deletion
strain than in the wild-type strain. Furthermore, the UPP synthetase encoded by uppS,
which is not part of the M regulon, did not show differential expression between the
two strains (Fig. 4B). These results suggest that the upregulation of early steps of UPP
synthesis in a bcrC deletion mutant may increase the overall abundance of lipid carriers
in the lipid II cycle, thereby counteracting the bottleneck induced by UPP phosphatase
deletion.
FIG 4 Calibration of a model integrating the lipid II cycle with the BcrC resistance module. (A) Combining the lipid II cycle module with
the BcrC module (cf. Fig. 2A) leads to a model describing a ΔbceABmutant strain. Predictions of this model for the IC50 value (the bacitracin
concentration at which the PG synthesis rate declines to 50% of the unperturbed value) are shown under various contributions of BcrC
(xBcrC) to the overall UPP phosphatase activity (red line). The linear increase of the IC50 value with xBcrC is the result of the stronger overall
phosphatase activity incurred by BcrC upregulation (cf. Fig. 3C and D). The dotted line shows the experimental MIC of bacitracin in a
ΔbceAB mutant, and the red star indicates the optimal parameter obtained by in our constrained optimization approach (see Text S1). (B)
In the absence of bacitracin, expression of ispD and ispF is upregulated in a ΔbcrC mutant relative to the B. subtilis wild type, as quantiﬁed
by RT-qPCR as described in Materials and Methods. Given that ispD and ispF are involved in early steps of UPP de novo synthesis, this
suggests that the deletion of bcrC triggers elevated levels of lipid II cycle intermediates, which may, in turn, compensate for the reduced
UPP dephosphorylation rate in this mutant. (C) Predictions of the bacitracin IC50 in a model for the ΔbceAB ΔbcrC double mutant (see color
key) as a function of various contributions of BcrC to the overall UPP phosphatase activity (x axis) and the fold change of total lipid II cycle
intermediates as induced by the bcrC deletion (y axis). Within this model, the higher xBcrC in the model in the ΔbceAB mutant, the stronger
the bcrC deletion in the double mutant reduces the IC50 value. Accordingly, in order to achieve a similar IC50 value (same color in the
background), higher xBcrC fractions require higher upregulation of the total abundance of lipid II cycle intermediates in this model. The
dashed line indicates the experimental MIC of bacitracin in a ΔbceAB ΔbcrC double mutant. The parameters below the solid black line
represent physiologically plausible combinations, in which the PG synthesis rate in the mutant (jPGΔbceABΔbcrC) does not exceed the rate in
the wild-type (jPGWT). The red star indicates the optimal parameter set obtained by in our constrained optimization approach (see Text S1).
Piepenbreier et al.
January/February 2020 Volume 5 Issue 1 e00687-19 msystems.asm.org 8
 o
n
 February 7, 2020 at UNIV O
F BATH
http://m
system
s.asm
.org/
D
ow
nloaded from
 
Hence, we asked how a higher total concentration of the lipid II cycle intermediates
(in the following referred to as LII intermediates) would affect the model prediction for
a bcrC deletion mutant (see Text S1 for a detailed description). As we did not know the
precise change in LII intermediates in the bcrC deletion strain, we simulated the model
for different fold changes in LII intermediates and predicted the IC50 under bacitracin
treatment. In this study, it turned out that an increase in LII intermediates raises both
the lipid II concentrations and the overall PG synthesis rate (Fig. 5C) and thus ensures
progression of the lipid II cycle without bacitracin treatment, as suggested by the fact
that growth of the bcrC deletion strain was not drastically reduced compared to that of
the wild type (Fig. S1). Accordingly, the model predicts that higher levels of LII
intermediates in the ΔbceAB ΔbcrC mutant lead to higher IC50 values under bacitracin
treatment (Fig. 4C, dependence along vertical axis). The model also predicts that the
higher the contribution of BcrC to the overall phosphatase activity, the higher the
required fold change in LII intermediates to reach the same IC50 values in the ΔbceAB
ΔbcrC mutant (Fig. 4C, dependence along horizontal axis). This underlines the idea that
upregulation of LII intermediates can compensate for the lack of UPP phosphatase
activity. However, we also noted that some of the tested parameter combinations led
to predictions in which the PG synthesis rate in the mutant (jPGΔbceABΔbcrC) was higher
than the rate in the WT (jPGWT), which is physiologically implausible (Fig. 4C, shaded
area). Thus, to arrive at a physiologically plausible parameter set, we performed
parameter optimization to simultaneously ﬁt the experimental MIC values of the
ΔbceAB and ΔbceAB ΔbcrC mutant strains while meeting the constraint jPGΔbceABΔbcrC 
jPGWT. This resulted in a set of parameters in which BcrC was the dominant phosphatase
(xBcrC  63% [9.5%]) and in which the LII intermediate level was upregulated 6.2-fold
(0.7-fold), resulting in a close-to-optimal PG synthesis rate and IC50 predictions
ranging closely around the measured MICs for both mutant strains (Fig. 4A and C, red
stars). These results are in line with previous experimental studies with B. subtilis (16)
showing that a bcrC deletion led to a stronger reduction in resistance against bacitracin
than a deletion of uppP. Hence, by integrating the homeostatic control of the overall LII
intermediate level in response to a lack of BcrC, we arrived at a theoretical model that
FIG 5 Model-predicted distribution of lipid II (LII) cycle intermediates in the ΔbceAB and ΔbceAB ΔbcrC mutant strains. The distribution of the different lipid
II cycle intermediates without bacitracin treatment is highly asymmetric. The lipid II cycle is located around the cell membrane, which is indicated in gray. Lipid
II cycle intermediates are illustrated with blue circles, while the size of the circles correlates with the concentration of the respective intermediate. UPPOUT, UPOUT,
and LIIOUT represent the fraction the intermediates UPP, UP, and lipid II, respectively, which is located at the outer leaﬂet of the cell membrane. Accordingly,
the fraction of intermediates located at the inner leaﬂet of the cell membrane is described by UPIN and LIIIN. UPPIN is not displayed, as this lipid intermediate
is not directly involved in the lipid II cycle. Lipid I (LI) is present solely on the inner leaﬂet of the cell membrane. The de novo synthesis of new lipid carrier in
the form of UPP is indicated. The thickness of the arrows correlates with the ﬂuxes from one intermediate state into the next one within the lipid II cycle. In
addition, the rate of PG synthesis is displayed. (A) When BceAB is lacking (ΔbceAB), the concentrations of the various lipid II cycle intermediates equal the
concentrations predicted in the basic model without bacitracin stress response determinants (34). While UPPOUT is most abundant, the concentrations of LI, LIIIN,
and LIIOUT are 2 orders of magnitude lower. UPIN and UPOUT are present in intermediate concentrations. (B) When bcrC is additionally deleted (ΔbceAB ΔbcrC),
the rate of UPP dephosphorylation is signiﬁcantly reduced and lipid intermediates accumulate in the form of UPPOUT, as this is the substrate of the respective
reaction. Since the lipid II cycle is a closed-loop system (34), all other concentrations are depleted concomitantly. However, as UPPOUT is still the most abundant
intermediate in the lipid II cycle, its concentration is not raised signiﬁcantly. The distinct reduction (50%) of the concentrations of UPOUT, UPIN, LI, LIIIN, and
LIIOUT leads to signiﬁcantly reduced ﬂuxes within the lipid II cycle. In particular, the reduction of the concentration of LIIOUT of 75% leads to a decreased rate
of PG synthesis, far below the half-maximal level. (C) However, the model predicts a nearly unaffected rate of PG synthesis when a 6.6-fold increase in total
lipid intermediates (caused by a higher rate of UPP de novo synthesis) in response to bcrC deletion is expected. While the concentration of UPPOUT is massively
increased, all other lipid II cycle intermediates are as abundant as in the ΔbceABmutant scenario. Consequently, the similar concentrations of LIIOUT imply similar
rates of PG synthesis in both the mutant lacking BceAB exclusively (ΔbceAB) and the mutant lacking both resistance modules (ΔbceAB ΔbcrC).
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quantiﬁes the impact of BcrC as a secondary resistance module on the progression of
the lipid II cycle, both in the absence and in the presence of bacitracin.
Interaction between the BcrC and BceAB resistance modules. Next, we focused
on the interplay between the primary and secondary resistance modules BceAB and
BcrC, respectively. As noted above, it turned out that the presence of BceAB in the wild
type mitigates the demand for bcrC expression, as reﬂected in an 2-fold-lower
induction in PbcrC activity upon bacitracin treatment in the wild type than in the ΔbceAB
mutant (Fig. 2Bi, black versus green line). We found that the PbceA promoter displays an
10-fold-lower activity in the wild type compared to a ΔbcrC mutant, suggesting that
also the presence of BcrC reduces the demand for bceAB expression in wild-type cells.
These results clearly indicate a high level of cross-regulation between the resistance
modules, which we wanted to rationalize via our computational model.
In order to complete the computational model of the bacitracin resistance network
in the B. subtilis wild type, we next integrated the BceAB transporter into our theory of
the lipid II cycle. To this end, we took advantage of a previously developed theoretical
description of the BceAB resistance module in B. subtilis (21). Brieﬂy, this model is based
on differential equations describing the binding of bacitracin (BAC) to UPP (yielding
UPP-BAC complexes), the upregulation of bceAB expression in response to increasing
UPP-BAC complexes and ultimately the release of bacitracin from UPP catalyzed by
increasing BceAB transporters levels. Here, the relative bacitracin ﬂux (JBAC) experienced
by each BceAB transporter is described by Michaelis-Menten kinetics,
JBAC
UPP-BAC
Km UPP-BAC
Where Km is the UPP-BAC concentration at which the catalytic rate of BceAB reaches its
half-maximal value. Importantly, within this model JBAC not only sets the rate at which
UPP is released from the inhibitory grip of bacitracin but also regulates expression of
bceAB expression via the ﬂux-sensing mechanism depicted in Fig. 2A and as detailed in
Text S1. Combining this model for the BceAB module with the equations for the lipid
II cycle, including the bacitracin-dependent upregulation of the BcrC module, ulti-
mately led us to a comprehensive computational model for both resistance modules in
the B. subtilis wild-type strain (see Text S1 for a detailed model description).
We then asked whether this full model is in quantitative agreement with the data
describing the bacitracin response of the BceAB module in wild-type cells. To this end,
we ﬁxed all parameters for the lipid II cycle to the optimal values derived above and
imposed that the regulation of BcrC protein levels is proportional to the PbcrC promoter
activity measured in the wild-type strain (Fig. 2Bi, black data). Then we estimated the
additional parameters describing the induction of the BceAB resistance module by a ﬁt
to the experimental PbceA promoter activity (Fig. 2Biii, black data; see Materials and
Methods for details of the ﬁtting procedure and Table S3 for parameter values). This led
us to a parameter combination for which the model output closely resembles the
observed response of PbceA toward bacitracin (Fig. 6A), suggesting that the model
accurately captures the cross-regulation between the two resistance modules. Impor-
tantly, when studying the PG synthesis rate within this model (Fig. 6B, black line), it
turned out that with increasing bacitracin concentration the increasing production of
BcrC and BceAB stabilized the PG synthesis rate even in the presence of bacitracin and
increased the IC50 to a value close to the MIC experimentally measured in the wild-type
strain (Fig. 6B, black star; MICWT, 125 g/ml). These results show that the computa-
tional model of the bacitracin resistance network now precisely rebuilds the interplay
of the two resistance modules and suggests that the simultaneous inductions of the
two resistance modules jointly mediate lipid II cycle homeostasis under bacitracin
treatment.
To further test the validity of our model, we demanded that it should be able to
correctly predict the behavior of a ΔbcrC strain, in which BceAB is the sole genuine
resistance determinant under bacitracin treatment (Fig. 6A, red data points). Due to the
lack of BcrC in this strain, our model predicts that these cells produce higher levels of
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LII intermediates (similar to the ΔbcrC ΔbceAB double mutant), which also lead to a
higher abundance of UPP in the cell. This increased exposure of UPP then leads to
higher levels of the bacitracin-bound form UPP-BAC in the presence of the antibiotic,
which, in turn, serves as the stimulus for the activation of the PbceA promoter via the
previously described ﬂux-sensing mechanism. Accordingly, our model predicts that the
accumulation of UPP-BAC in the ΔbcrC strain triggers an 10-fold-higher PbceA pro-
moter activity than with the wild-type strain (Fig. 6A, red dashed line), in qualitative
agreement with the increased PbceA activity in the ΔbcrC strain determined experimen-
tally (Fig. 6A, red data points). Also, without invoking any further parameter ﬁtting, for
a strain lacking BcrC the model-predicted IC50ΔbcrC of 22 g/ml closely matches the
FIG 6 Model calibration of the BceAB resistance module and MIC predictions in B. subtilis wild-type and
mutant strains. (A) Fit of the full model for the bacitracin resistance network (including the BceAB
module) to the experimental dose-response characteristic of the PbceA-luxABCDE reporter in B. subtilis
wild-type (WT) cells. The red dashed line shows the model prediction for the ΔbcrC mutant without
invoking further ﬁt parameters, revealing that although the model captures the overall increase in PbceA
activity under bacitracin treatment, it does not describe the elevated basal promoter activity in the
absence of bacitracin (see Text S1 for details). The red solid line shows the prediction of the model when
the BceAB/BceS ﬂux-sensing complex recognizes unbound UPP as a secondary substrate, which leads to
a futile ﬂux and triggers signaling in the BceRS two-component system. (B) The model behavior of the
PG synthesis rate under bacitracin treatment for B. subtilis wild-type and mutant cells generates
predictions for the respective IC50 values (arrows), which are close to the experimental MIC values of the
corresponding strains. (C) Schematic model behavior in the wild type and ΔbcrC mutant at identical
bacitracin concentrations, illustrating that the higher UPP pool in the ΔbcrC mutant leads to higher
UPP-BAC levels and thus to stronger activation of the BceRS signaling cascade than with the wild type.
Modeling Bacitracin Resistance in B. subtilis
January/February 2020 Volume 5 Issue 1 e00687-19 msystems.asm.org 11
 o
n
 February 7, 2020 at UNIV O
F BATH
http://m
system
s.asm
.org/
D
ow
nloaded from
 
experimentally determined MIC of a ΔbcrC mutant (Fig. 6B; MICΔbcrC, 25 g/ml). This
suggests that the simulated response of the BceAB resistance module—in conjunction
with the elevated pool of LII intermediates—accurately capture the physiology of the
system under bacitracin treatment.
One striking discrepancy between our model and the experimental data, however,
was visible in the absence of bacitracin, where our experiments showed that the
promoter activity of PbceA was also 10-fold higher than in the wild type (Fig. 6A). This
result is not compatible with the idea that UPP-BAC is the sole substrate for the
ﬂux-sensing mechanism via the BceAB transporter (triggering the activation of PbceA),
because UPP-BAC cannot be formed in the absence of bacitracin and thus the signaling
mechanism should be inactive. However, it was previously hypothesized that UPP itself
somehow triggers (futile?) ATP hydrolysis by BceAB and that high levels of UPP may
contribute to the activation of PbceA (26, 36). Such an interaction seems plausible, given
that the recognition of the UPP-BAC complex by BceAB likely involves interactions with
both the UPP as well as the BAC moieties, raising the possibility that BceAB has some
residual afﬁnity for UPP. Interestingly, as noted above, the model predicts a signiﬁcantly
higher concentration of UPP in the ΔbcrC mutant than in the wild type (Fig. 5C), as
caused by the expected increase of the overall concentration lipid II cycle intermediates
as well as the reduced overall phosphatase activity in the absence of BcrC. To test if
futile activation of PbceA by these elevated UPP levels can explain the higher basal
promoter activity observed in the ΔbcrC mutant, we modiﬁed the theoretical descrip-
tion of the total load per BceAB transporter, Jload, which is proportional to the rate of
ATP hydrolysis and, in turn, regulates the promoter activity of PbceA, as follows:
Jload JBAC
'  Jfutile
where
JBAC
' 
UPP-BAC
Km
⁄ 1 UPP-BACKm  UPPK˜m 
describes the ﬂux of bacitracin released from UPP-BAC complexes and
Jfutile
UPP
K˜m
⁄ 1 UPP-BACKm  UPPK˜m 
describes the rate of futile ATP hydrolysis triggered by UPP alone, with Michaelis
constants K˜m and Km describing the binding constants of the transporter for UPP and
UPP-BAC, respectively. Within these equations an increasing level of UPP increases the
overall load per transporter, Jload, which then triggers signaling and activation of PbceA,
while the same increase in UPP leads to a reduction of the ﬂux of bacitracin release,
JBAC
' , induced by competitive binding to the transporter. Strikingly, by modifying the
model as depicted, the predictions of PbceA promoter activation differed signiﬁcantly
between the simulated scenarios (Fig. 6A, red solid line). While the model output for the
wild-type equaled the prediction of the former model, the modiﬁed model predicted a
signiﬁcant elevation of PbceA promoter activities in a strain lacking BcrC, which closely
resembles the experimental data for the ΔbcrC strain (Fig. 6A). Thus, our results of the
modiﬁed model support the hypothesis of futile activation of PbceA by UPP under BcrC
deletion (Fig. 6C). However, since the model modiﬁcations did not affect the IC50
predictions of the various mutants (see Text S1), the effect of UPP on PbceA activation
is likely negligible under bacitracin treatment and solely affects the level of basal
promoter activity.
DISCUSSION
Building on the experimental characterization of the bacitracin resistance network in
B. subtilis (26), we here present the ﬁrst theoretical description of this regulatory
network. The mathematical model developed in this study not only accurately predicts
the efﬁcacy of bacitracin in the wild type and various mutant strains lacking one or both
of the resistance modules (Fig. 6B) but also uncovers important regulatory features of
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the resistance network. By successively incorporating mathematical descriptions of the
individual resistance modules into a preexisting theory of the lipid II cycle, we showed
that the interplay between the two major resistance determinants (BceAB and BcrC) is
strictly linked to the properties of the lipid II cycle, which change in response to
bacitracin.
One important insight of our analysis is that BcrC is the more dominant UPP
phosphatase than UppP, dictating the bulk of the overall UPP recycling rate in the lipid
II cycle of B. subtilis. This is also reﬂected by the fact that bcrC expression is signiﬁcantly
elevated under bacitracin stress (Fig. 2Bi), while uppP is constitutively expressed
(14–16), implying even more pronounced changes in the total phosphatase activity in
response to bacitracin than previously appreciated. These results are in accordance
with experiments showing that a bcrC deletion signiﬁcantly reduced the resistance
toward bacitracin in B. subtilis, while a deletion of uppP had only moderate effects (14,
16). In fact, to ensure a strong protective effect in response to cell envelope stress, it
seems physiologically plausible for the cell to activate expression of the phosphatase
contributing most strongly to the progression of the lipid II cycle.
Another ﬁnding arising from the combination of theory and experiment was the
homeostatic control of lipid II cycle intermediate levels in a ΔbcrC mutant, ensuring the
close-to-optimal progression of the cycle despite the lack of the important phosphatase
BcrC. We found two M-controlled genes, ispD and ispF, involved in the de novo
synthesis of UPP, to be signiﬁcantly upregulated, which counteracted the depletion of
the lipid II pool caused by a shortage of UPP phosphatase activity. While we did not
directly prove that this leads to an increase in the overall abundance of lipid II cycle
intermediates, our experimental and theoretical results indirectly support this hypoth-
esis in three ways. (i) The ΔbcrC ΔbceAB double mutant is signiﬁcantly more resistant to
bacitracin than naively predicted by a model with constant total lipid II cycle interme-
diate pools, suggesting that a compensatory upregulation of these pools contributes to
bacitracin resistance in this mutant. (ii) Under bacitracin treatment, the PbceA promoter
is 10-fold more active in a ΔbcrC mutant than in the wild type, suggesting that the
major substrate, UPP-BAC, of the BceAB transporter is more abundant in the mutant,
which, in turn, triggers stronger activation of PbceA via the ﬂux-sensing mechanism
described in reference 21. (iii) Even in the absence of bacitracin, the ΔbcrC mutant
displays an 10-fold-higher PbceA activity than the wild type, suggesting that the
elevated UPP pool in this mutant is sufﬁcient to trigger some futile ATP hydrolysis by
the BceAB transporter, which then activates PbceA via the ﬂux-sensing mechanism.
From a systems-level perspective, the upregulation of lipid carrier production seems
to be a particularly elegant way to maintain cycle homeostasis under antibiotic
treatment, because it naturally preserves the relative balance between the different
lipid II cycle intermediates. In fact, in a closed-loop system like the lipid II cycle, the
stoichiometry between the intermediate pools is determined only by the catalytic rates
and abundances of the enzymes catalyzing cycle progression and not the overall
abundance of all intermediates (34). Thus, the sequestration of one cycle intermediate
by an antibiotic (such as bacitracin, vancomycin, or nisin) will lead to the stoichiometric
reduction of all other intermediates. One possible way to accelerate lipid II cycle
progression would be the simultaneous upregulation of all lipid II cycle-associated
enzymes. In contrast to such a ﬁne-tuned, orchestrated regulation, our results suggest
that the cell compensates this shortage by de novo synthesis of cycle intermediates,
which rapidly equilibrates among the different stages of the lipid II cycle intermediates
and naturally replenishes intermediate levels in the correct stoichiometry. We suggest
that this strategy implements a robust way of ensuring lipid II cycle homeostasis.
Although we did not decipher the exact stimulus for activation of the BcrC resis-
tance module, our theory revealed that the regulation of bcrC expression and regula-
tion of bceAB expression are tightly interconnected via the properties of the lipid II cycle
itself. Since the activation of the resistance determinants in response to bacitracin go
along with signiﬁcant changes in the concentrations of the different lipid II cycle
intermediates, it is plausible that not only BceAB but also the BcrC resistance module
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somehow responds to these changes. Indeed, it seems advantageous to regulate the
overall resistance against bacitracin by responding to changes in the properties of the
lipid II cycle, since this does not demand additional regulatory structures for each
resistance module, which might be costly to produce and would further complicate the
resistance network. More generally, monitoring the physiological state of the pathway
itself may serve as a cost-effective strategy to regulate the interplay between the
different resistance determinants protecting the cell against cell envelope stress.
Ultimately, this study clearly highlights how mathematical modeling provides a
better understanding of sophisticated cellular responses toward environmental condi-
tions, in particular antibiotic treatment. By combining existing theoretical descriptions
of the various modules of the cellular response, a comprehensive model of the complex
network structure evolved. Successive integration of additional modules of the cellular
response into the growing model enabled us to study both the basal regulatory
features of every individual layer and the factors determining the interplay between
them within the whole network. We showed that a simple existing model can be
expanded to develop a more and more complex picture, and eventually the model
itself could even become a building block when describing a network on a broader
scale. This approach can act as a blueprint for acquiring true systems-level understand-
ing of complex regulatory structures, describing not only the organization of resistance
system against other antibiotics but also more generally multitiered response networks
that can be expected across many bacterial species and a range of environmental
stressors.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacillus subtilis and Escherichia coli were routinely grown
in lysogeny broth (LB medium) at 37°C with agitation (200 rpm). Transformations of B. subtilis were
carried out as described previously (37). All strains used in this study are derivatives of the wild-type
strain W168 and are listed in Table S1. Kanamycin (10 mg ml1), chloramphenicol (5 mg ml1), tetracy-
cline (10 mg ml1), and erythromycin (1 mg ml1) plus lincomycin (25 mg ml1) for macrolide-
lincosamide-streptogramin B (MLS) resistance were used for the selection of the B. subtilis mutants used
in this study. Solid media contained 1.5% (wt/vol) agar.
Luciferase assays. Luciferase activities of B. subtilis strains harboring pAH328 derivatives were
assayed using a Synergy2 multimode microplate reader from BioTek (Winooski, VT), essentially as
described in reference 26. Brieﬂy, the reader was controlled using the software Gen5 (version 2.06). Cells
were inoculated 1:1,000 from fresh overnight cultures and grown to an optical density at 600 nm (OD600)
of 0.1 to 0.5. Subsequently, cultures were diluted to an OD600 of 0.01 and split into 100 l per well in
96-well plates (black walls, clear bottom; Greiner Bio-One, Frickenhausen, Germany). Cultures were
incubated at 37°C with linear agitation (medium intensity), and the OD600 and luminescence were
monitored every 3 min. After 1 h, freshly diluted Zn2-bacitracin was added to the desired ﬁnal
concentrations, and incubation and monitoring every 3 min were resumed for 8 h. Speciﬁc luminescence
activity is given by the raw luminescence output (relative luminescence units [RLU]) normalized by cell
density (RLU/OD600). Please note that the luminescence sensitivity of the microplate reader used in this
study is lower than in our previous work (26), such that for a given strain the relative luminescence units
reported here are 10- to 50-fold lower than previously reported. Also, in the present work we used a
more stringent cleaning procedure for test tubes (used for overnight and day cultures), which completely
avoids the use of detergents and instead relies on mechanical cleaning and autoclaving only. With this
procedure we found that the basal expression of cell wall stress modules (in the absence of antibiotics)
is slightly lower than with the previous procedure, explaining, for instance, why the observed lumines-
cence activity of the PbceA-lux construct in Fig. 2Biii remained at a low level between 0 g/ml and
3 102 g/ml of bacitracin and increased only at higher antibiotic concentrations, while we found a
slight increase of luminescence activity at these concentrations before (26). These subtle differences in
expression levels affected the qualitative behavior only under noninduced conditions (no bacitracin) and
neither impacted the development of the computational model nor affected the conclusions from this
work.
MIC assays. For concentration-dependent growth experiments, cells were grown as described for
the luciferase assays and OD600 was measured analogously. The growth rate within the ﬁrst hour after
bacitracin addition was determined to monitor the concentration-dependent effects of bacitracin on cell
growth (Fig. 2Bi). The MIC was deﬁned as the concentration of antibiotic that fully inhibited growth, i.e.,
for which the growth rate equals zero.
Relative quantitative RT-PCR. Bacillus subtilis W168 and ΔbcrC cells were collected at an OD600
between 0.3 and 0.5 (measured in a spectrophotometer) and suspended in TRIzol (Ambion). The cells
were lysed through bead beating with 0.1-mm zirconia beads. RNA was extracted from exponentially
growing cells with TRIzol reagent. DNA was removed with DNase (Thermo Scientiﬁc) and the DNase was
then heat deactivated in the presence of EDTA. RT-qPCR was performed with the Luna universal one-step
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RT-qPCR kit (New England Biolabs). One microliter of 10-fold-diluted RNA was added to 4 l of RT-PCR
mix and subjected to a reverse transcription step at 55°C and 45 cycles of PCR (10 s at 95°C and 30 s at
60°C). The average threshold cycle (CT) value of three technical replicates of three biological replicates for
each sample was used in ΔΔCT relative expression analysis (38). The reference genes were the consti-
tutively expressed genes recA (BSU16940) and gyrB (BSU00060).
Computational model and simulations. A detailed description of the model assumptions and
equations for the bacitracin resistance network and additional analyses of the model are given in Text
S1. The numerical calculations of the differential equations of the model as well as the individual
simulations were performed with custom scripts developed in MATLAB software (The MathWorks, Inc.).
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